How to Get Vyleesi in Minnesota

What Vyleesi Is and Why Minnesota Providers Prescribe It

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist that the FDA approved in June 2019 specifically for acquired, generalized HSDD in premenopausal women [1]. It is the only on-demand injectable treatment for this condition. The drug works centrally in the hypothalamus rather than peripherally, distinguishing it from flibanserin (Addyi), which requires daily oral dosing.

The two key RECONNECT trials (pooled N=1,247) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in satisfying sexual events (SSEs) of approximately 0.5 more per month compared with placebo (P=0.0002), alongside a meaningful reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [2]. While 0.5 SSEs per month may sound modest, the distress reduction was the outcome most patients reported as clinically meaningful according to the FDA's clinical review.

Minnesota law permits any provider with prescriptive authority to prescribe Vyleesi. That includes physicians (MD/DO), nurse practitioners, and physician assistants. No state-specific restrictions exist beyond standard controlled-substance rules, and bremelanotide is not a scheduled substance.

Step-by-Step: Getting a Vyleesi Prescription in Minnesota

The prescription process follows a predictable clinical pathway, whether you see a provider in person at a Minnesota clinic or connect through a telehealth platform. Here is what to expect.

1. Initial clinical evaluation. Your provider will screen for HSDD using validated instruments like the Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI). The diagnosis requires low sexual desire that causes personal distress and is not explained by another medical condition, psychiatric disorder, relationship factors, or medication side effects [3].

2. Rule-out workup. Before prescribing, most providers order baseline labs. A standard panel includes thyroid-stimulating hormone (TSH), prolactin, complete metabolic panel, and sometimes total and free testosterone. Depression screening with the PHQ-9 is typical because SSRIs and SNRIs are a common reversible cause of low desire. Blood pressure measurement is required at baseline because bremelanotide can cause transient hypertension (mean increase of 6 mmHg systolic) [1].

3. Prescription and pharmacy routing. Once HSDD is confirmed and contraindications are ruled out, your provider writes the prescription. You can fill it at a specialty pharmacy that stocks Vyleesi, use a mail-order pharmacy, or have it compounded through a Minnesota-licensed 503A pharmacy if cost is a concern.

4. Self-injection training. Vyleesi is delivered via a single-dose, prefilled autoinjector (1.75 mg/0.3 mL) into the abdomen or thigh. Training takes roughly five minutes and can be done during a telehealth video visit with a live demonstration using a training pen.

Patients who already hold a valid Vyleesi prescription from another state can transfer it to a Minnesota pharmacy. The receiving pharmacist contacts the originating pharmacy to verify the prescription, a process that typically completes within one to two business days.

Telehealth Access: How Minnesota Patients Connect with Prescribers Online

Minnesota has some of the most permissive telehealth statutes in the Upper Midwest. The state does not require an in-person visit before prescribing non-controlled medications, and bremelanotide carries no DEA schedule [4]. This means a licensed provider can evaluate, diagnose, and prescribe Vyleesi entirely through a synchronous video or audio visit.

Several telehealth models serve Minnesota patients. Platform-based services (including HealthRX) connect patients with licensed prescribers who specialize in sexual medicine. Direct-to-consumer startups also offer HSDD evaluations, though patients should verify that the prescribing clinician holds an active Minnesota license through the Minnesota Board of Medical Practice or the Minnesota Board of Nursing.

Telehealth visits for HSDD typically last 15 to 30 minutes. The provider reviews symptoms, medical history, current medications, and any recent lab work. If labs are needed, the provider orders them through a commercial lab network (Quest, Labcorp, or a local Minnesota health system). Results usually return within 48 to 72 hours, after which the provider finalizes the prescription.

One practical advantage of telehealth: follow-up titration and nausea management can happen asynchronously through the platform's messaging system rather than requiring a return office visit. The FDA label recommends that patients who experience nausea take the injection with food or consider pretreatment with an antiemetic, a conversation that fits well into a secure message exchange [1].

Pharmacy Options and 503A Compounding in Minnesota

Three pharmacy pathways exist for Minnesota patients filling a bremelanotide prescription. Each differs in cost, speed, and product form.

Brand Vyleesi (Palatin Technologies). The brand autoinjector carries a wholesale acquisition cost (WAC) of approximately $950 per dose. Palatin offers a savings card that may reduce out-of-pocket costs for commercially insured patients, though coverage varies by plan. Specialty pharmacies like Optum Specialty, CVS Specialty, and Accredo typically stock it. Delivery to a Minnesota address runs 3 to 7 business days after prior authorization clears.

503A compounding pharmacies. Minnesota licenses 503A pharmacies under Minnesota Statutes § 151.21, allowing them to compound patient-specific prescriptions, including bremelanotide, when a valid prescription exists. Compounded bremelanotide is dispensed as a multi-dose vial with insulin syringes rather than a prefilled autoinjector. Cost typically falls between $80 and $200 per month depending on the pharmacy and number of doses compounded. Patients must have a prescription from a licensed provider specifying the compounded formulation.

Mail-order specialty pharmacy. For patients outside the Twin Cities metro or in rural Minnesota, mail-order remains the most convenient route. Most specialty pharmacies ship overnight with cold-chain packaging when needed, though bremelanotide is stable at room temperature (20-25°C) and does not require refrigeration after dispensing [1].

Turnaround time from prescription to first dose averages 5 to 10 business days when no prior authorization is required. With PA, add 3 to 5 business days for insurer review.

Prior Authorization and Insurance Coverage in Minnesota

Minnesota Medicaid (Medical Assistance) covers Vyleesi with prior authorization [5]. The PA process requires documentation that the patient meets all of the following criteria: premenopausal status, a clinical diagnosis of acquired generalized HSDD, distress related to low desire, and exclusion of alternative causes (medication-induced, psychiatric, endocrine).

Commercial insurers in Minnesota vary in their formulary placement of Vyleesi. Some plans place it on a specialty tier (Tier 4 or 5) with a copay ranging from $75 to $250 per fill. Others exclude it entirely, requiring an appeal or a switch to the compounded route.

The PA submission typically includes these documents:

• A letter of medical necessity from the prescribing provider
• Chart notes documenting HSDD diagnosis and duration (most insurers require symptoms for ≥6 months)
• Lab results ruling out thyroid dysfunction, hyperprolactinemia, and hormonal causes
• Documentation that the low desire is not attributable solely to a mental health condition or relationship issue
• A note confirming the patient is premenopausal

Processing times for Minnesota Medicaid PA requests average 3 to 5 business days. For urgent requests (labeled as such by the provider), the state requires a response within 24 hours. If denied, patients have the right to appeal through the Minnesota Department of Human Services fair hearing process.

A 2021 analysis published in the Journal of Managed Care & Specialty Pharmacy found that among commercially insured women with HSDD diagnoses, only 28.6% of initial PA requests for bremelanotide were approved on first submission, though the approval rate rose to 59% after appeal [6]. Detailed clinical documentation at the initial submission stage can reduce the likelihood of denial.

Who Can Prescribe Vyleesi in Minnesota: MD, NP, PA, and Beyond

Minnesota grants full prescriptive authority to several provider categories. Any of the following can legally prescribe bremelanotide in Minnesota without a collaborative practice agreement for this medication class:

• Physicians (MD/DO): Board-certified in obstetrics-gynecology, family medicine, internal medicine, psychiatry, or sexual medicine. No specialty restriction exists in statute.
• Nurse practitioners (NP): Minnesota NPs with an APRN license have independent prescriptive authority for non-controlled substances. No physician co-signature is needed [7].
• Physician assistants (PA): Minnesota PAs prescribe under a delegation agreement with a supervising physician, though the agreement does not require the physician to co-sign each prescription for non-scheduled drugs.

Providers who most frequently prescribe bremelanotide in clinical practice include OB-GYNs, sexual medicine specialists, and primary care clinicians who have integrated HSDD screening into well-woman visits. The ISSWSH clinical practice guideline (2018) recommends that any clinician comfortable diagnosing and managing HSDD can prescribe approved pharmacotherapy, provided they conduct appropriate screening and follow-up [8].

Clinical Monitoring After Starting Vyleesi

Bremelanotide does not require the intensive monitoring profile of some other sexual health medications. Post-prescribing follow-up is straightforward.

Blood pressure. Because MC4R activation produces transient increases in blood pressure (peak at approximately 2 to 3 hours post-injection, resolving within 12 hours), the FDA label advises against use in patients with uncontrolled hypertension or known cardiovascular disease [1]. A follow-up blood pressure check 4 to 8 weeks after initiation is reasonable clinical practice, though not mandated by the label.

Nausea management. Nausea is the most common adverse event, reported by 40.0% of bremelanotide-treated patients versus 1.3% on placebo in RECONNECT [2]. The nausea is dose-dependent, peaks within 1 to 2 hours, and diminishes with repeated use in most patients. Among women who continued treatment beyond the first three doses, nausea rates dropped to approximately 20% by dose six. Ondansetron 4 mg taken 30 minutes before the bremelanotide injection is an off-label but widely used pretreatment strategy.

Skin hyperpigmentation. Bremelanotide can cause focal hyperpigmentation, particularly of the face, gingiva, and breasts, due to melanocortin-1 receptor cross-activation. In the RECONNECT trials, 1.0% of treated patients reported darkening of skin or gums [2]. The effect is generally reversible after discontinuation but may take weeks to resolve. Providers should counsel patients about this possibility at the time of prescribing, especially patients with lighter skin tones who may notice changes earlier.

Efficacy reassessment. The FDA label recommends discontinuing Vyleesi if no meaningful improvement occurs after 8 weeks (approximately 8 doses) of use [1]. Clinicians should schedule a follow-up at the 8-week mark to assess whether the patient has experienced an increase in desire, a reduction in distress, or both.

Cost Comparison: Brand Vyleesi vs. Compounded Bremelanotide in Minnesota

Cost is the single largest barrier to Vyleesi access for most Minnesota patients. The table below illustrates typical out-of-pocket scenarios.

| Route | Approximate cost per dose | Monthly cost (4 doses) | Notes | |---|---|---|---| | Brand Vyleesi (no insurance) | $850-$950 | $3,400-$3,800 | Palatin savings card may reduce to $50-$100/dose for eligible patients | | Brand Vyleesi (commercial insurance, Tier 4) | $75-$250 copay | $75-$250 per fill | Varies widely by plan; PA often required | | Brand Vyleesi (MN Medicaid with PA) | $0-$3 | $0-$3 | Covered after prior authorization approval | | Compounded bremelanotide (503A) | $20-$50 | $80-$200 | Multi-dose vial; requires insulin syringes |

For patients without insurance coverage, compounded bremelanotide through a Minnesota 503A pharmacy represents the most cost-effective path. The compound uses the same active pharmaceutical ingredient at the same 1.75 mg dose, delivered subcutaneously via a standard insulin syringe rather than the branded autoinjector device.

Patients considering the compounded route should confirm that their pharmacy sources bremelanotide from an FDA-registered supplier and performs potency testing on each batch. The FDA's guidance on 503A compounding outlines the regulatory framework that governs these preparations [9].

Contraindications Specific to the Minnesota Patient Population

Two contraindications in the bremelanotide label deserve emphasis for Minnesota prescribers. First, bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease due to the transient blood pressure elevation [1]. Minnesota's adult hypertension prevalence is approximately 29%, close to the national average of 30%, making blood pressure screening at baseline non-negotiable [10].

Second, bremelanotide should not be used concurrently with naltrexone or naltrexone-containing medications (e.g., Contrave for weight management) because naltrexone blocks the opioid-receptor-mediated component of bremelanotide's mechanism. The FDA label lists this as a specific drug interaction [1]. Given the rising use of GLP-1 agonists and adjunctive naltrexone for weight loss, Minnesota prescribers should screen medication lists carefully before initiating Vyleesi.

Patients who are postmenopausal do not have an FDA-approved indication for bremelanotide. Off-label use in postmenopausal women is an area of active research but lacks the Phase III evidence base that supported the premenopausal approval. The RECONNECT trials enrolled only premenopausal women aged 21 and older with a mean age of 39 years [2].